Mom holding hands with her young son, who is in a wheelchair.
Correct the message.
Change a life.
A novel class of RNA-targeted gene
therapies—
to transform the lives of 
patients living with
rare genetic
diseases
Mom holding hands with her young son, who is in a wheelchair.
Correct the message.
Change a life.
A novel class of RNA-targeted gene
therapies—
to transform the lives of 
patients living with
rare genetic
diseases
Abstract representation of RNA.

A novel class
of genetic medicines

Many rare diseases are caused by genetic mutations resulting in disease-causing RNA transcripts. Locanabio’s pioneering platform of RNA-binding systems specifically targets these RNA transcripts and modifies them.

The versatility of our RNA-binding systems allows us to use a variety of mechanisms to target and correct faulty RNA. By combining the specificity of RNA-binding systems with the lasting effect of a one-time gene therapy, we can durably address the disease-causing RNA in patients suffering from a range of rare genetic neuromuscular and neurodegenerative diseases without altering their DNA.

Versatile, Modular
Platform

Learn how our platform can target and correct disease-causing RNA

Diversified
Pipeline

We are developing a portfolio of RNA-targeted therapies to address rare genetic neuromuscular and neurodegenerative diseases
Scientists in a Locanabio laboratory discussing RNA-related research.

DIVERSITY, EQUITY
& INCLUSION

Inclusion lies at the heart of our company—learn more about our diversity in action

Inspiring
Careers

Explore exciting careers at a company committed to making a positive difference in the lives of patients with rare genetic diseases